financetom
Business
financetom
/
Business
/
Maze Therapeutics Names Misbah Tahir as Chief Financial Officer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Maze Therapeutics Names Misbah Tahir as Chief Financial Officer
Sep 2, 2025 5:08 AM

07:42 AM EDT, 09/02/2025 (MT Newswires) -- Maze Therapeutics ( MAZE ) said Tuesday that Misbah Tahir was named as its chief financial officer, effective immediately.

Tahir most recently served as CFO of IGM Biosciences, according to Maze Therapeutics ( MAZE ).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SKYX Platforms Announces Six New Patents for Smart Ceiling Fan and Heater
SKYX Platforms Announces Six New Patents for Smart Ceiling Fan and Heater
Jun 24, 2024
10:21 AM EDT, 06/24/2024 (MT Newswires) -- SKYX Platforms ( SKYX ) said Monday it has been issued six additional patents in the US, China, India, Europe, Canada, and Mexico for its plug-and-play smart ceiling fan and heater. SKYX, a smart platform technology company, said it now has more than 94 issued and pending patents. Shares of the company were...
Advantage Energy Up More Than 2% As Closes $445 Million Deal for Charlie Lake, Montney Assets
Advantage Energy Up More Than 2% As Closes $445 Million Deal for Charlie Lake, Montney Assets
Jun 24, 2024
10:18 AM EDT, 06/24/2024 (MT Newswires) -- Advantage Energy ( AAVVF ) was at last look up more than 2% after saying Monday that it completed its previously announced acquisition of certain Charlie Lake and Montney assets from a private seller for $445 million, subject to closing adjustments. According to a statement, the acquisition was partially funded by a previously...
ChromaDex Says Nicotinamide Riboside Shows 'Promising Effects' in Peripheral Artery Disease Trial
ChromaDex Says Nicotinamide Riboside Shows 'Promising Effects' in Peripheral Artery Disease Trial
Jun 24, 2024
10:20 AM EDT, 06/24/2024 (MT Newswires) -- ChromaDex ( CDXC ) said Monday a phase 2 trial showed the promising effects of nicotinamide riboside supplementation in people with peripheral artery disease. The data showed benefits of nicotinamide riboside like an improvement in treadmill walking time and a statistically significant and clinically meaningful improvement in the six-minute walking distance in people...
DocGo Awarded 5 Health Care-Related Contracts
DocGo Awarded 5 Health Care-Related Contracts
Jun 24, 2024
10:14 AM EDT, 06/24/2024 (MT Newswires) -- DocGo ( DCGO ) said Monday it has been awarded five new contracts that will help expand accessibility to essential health care. The contracts cover remote patient monitoring, virtual care management, chronic care management, cardiac implantable electronic device and a care gap closure program, the company said. Shares of DocGo ( DCGO )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved